Pegloticase - Shanghai institute of biological products
Alternative Names: Peguricase for injection - Shanghai institute of biological products; SIBP-R002Latest Information Update: 28 Apr 2025
At a glance
- Originator Shanghai Institute of Biological Products
- Class Antigouts; Oxidoreductases; Polyethylene glycols; Recombinant proteins; Uricosurics
- Mechanism of Action Urate oxidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Gout
- No development reported Hyperuricaemia
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for phase-I development in Hyperuricaemia in China (IV, Infusion)
- 03 Mar 2023 Phase-I clinical trials in Gout (Treatment-experienced) in China (IV) (NCT06298071)
- 11 Apr 2022 Shanghai institute of biological products has patent protection for SIBP R002